nodes	percent_of_prediction	percent_of_DWPC	metapath
Rivaroxaban—CYP2J2—Cholecalciferol—psoriasis	0.415	0.531	CbGbCtD
Rivaroxaban—CYP3A5—Beclomethasone—psoriasis	0.0657	0.0841	CbGbCtD
Rivaroxaban—CYP3A5—Mycophenolate mofetil—psoriasis	0.0262	0.0335	CbGbCtD
Rivaroxaban—CYP3A4—Calcitriol—psoriasis	0.0228	0.0292	CbGbCtD
Rivaroxaban—CYP3A5—Hydrocortisone—psoriasis	0.021	0.0269	CbGbCtD
Rivaroxaban—CYP3A5—Cyclosporine—psoriasis	0.0198	0.0254	CbGbCtD
Rivaroxaban—CYP3A4—Methoxsalen—psoriasis	0.0178	0.0227	CbGbCtD
Rivaroxaban—ABCB1—Mycophenolate mofetil—psoriasis	0.017	0.0218	CbGbCtD
Rivaroxaban—ABCB1—Betamethasone—psoriasis	0.0146	0.0187	CbGbCtD
Rivaroxaban—ABCB1—Prednisolone—psoriasis	0.0144	0.0184	CbGbCtD
Rivaroxaban—ABCB1—Hydrocortisone—psoriasis	0.0137	0.0175	CbGbCtD
Rivaroxaban—ABCB1—Prednisone—psoriasis	0.0136	0.0174	CbGbCtD
Rivaroxaban—CYP3A5—Dexamethasone—psoriasis	0.0131	0.0167	CbGbCtD
Rivaroxaban—ABCB1—Cyclosporine—psoriasis	0.0129	0.0165	CbGbCtD
Rivaroxaban—CYP3A4—Cholecalciferol—psoriasis	0.0118	0.0151	CbGbCtD
Rivaroxaban—CYP3A4—Mycophenolate mofetil—psoriasis	0.0102	0.0131	CbGbCtD
Rivaroxaban—CYP3A4—Triamcinolone—psoriasis	0.0102	0.0131	CbGbCtD
Rivaroxaban—CYP3A4—Betamethasone—psoriasis	0.00875	0.0112	CbGbCtD
Rivaroxaban—CYP3A4—Prednisolone—psoriasis	0.00864	0.011	CbGbCtD
Rivaroxaban—ABCB1—Dexamethasone—psoriasis	0.0085	0.0109	CbGbCtD
Rivaroxaban—CYP3A4—Hydrocortisone—psoriasis	0.00819	0.0105	CbGbCtD
Rivaroxaban—CYP3A4—Prednisone—psoriasis	0.00816	0.0104	CbGbCtD
Rivaroxaban—CYP3A4—Cyclosporine—psoriasis	0.00773	0.00989	CbGbCtD
Rivaroxaban—ABCB1—Methotrexate—psoriasis	0.00683	0.00874	CbGbCtD
Rivaroxaban—CYP3A4—Dexamethasone—psoriasis	0.00509	0.00651	CbGbCtD
Rivaroxaban—CYP2J2—Xenobiotics—CYP2S1—psoriasis	0.00401	0.175	CbGpPWpGaD
Rivaroxaban—CYP2J2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00166	0.0726	CbGpPWpGaD
Rivaroxaban—CYP2J2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00164	0.0716	CbGpPWpGaD
Rivaroxaban—F10—Beta2 integrin cell surface interactions—ITGAL—psoriasis	0.0016	0.0699	CbGpPWpGaD
Rivaroxaban—CYP2J2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00135	0.0588	CbGpPWpGaD
Rivaroxaban—CYP3A5—Xenobiotics—CYP2S1—psoriasis	0.00115	0.0504	CbGpPWpGaD
Rivaroxaban—CYP2J2—Biological oxidations—CYP2S1—psoriasis	0.000716	0.0313	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metapathway biotransformation—CYP2S1—psoriasis	0.000707	0.0308	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—IL22—psoriasis	0.000699	0.0305	CbGpPWpGaD
Rivaroxaban—F10—Beta2 integrin cell surface interactions—ICAM1—psoriasis	0.000663	0.0289	CbGpPWpGaD
Rivaroxaban—CYP2J2—Tryptophan metabolism—CAT—psoriasis	0.000618	0.027	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—SERPINB8—psoriasis	0.00056	0.0244	CbGpPWpGaD
Rivaroxaban—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000537	0.0234	CbGpPWpGaD
Rivaroxaban—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00048	0.0209	CbGpPWpGaD
Rivaroxaban—CYP3A5—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000473	0.0206	CbGpPWpGaD
Rivaroxaban—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000389	0.017	CbGpPWpGaD
Rivaroxaban—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000289	0.0126	CbGpPWpGaD
Rivaroxaban—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000223	0.00972	CbGpPWpGaD
Rivaroxaban—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00022	0.0096	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—CYP2S1—psoriasis	0.000207	0.00901	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	0.000204	0.00888	CbGpPWpGaD
Rivaroxaban—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000181	0.00788	CbGpPWpGaD
Rivaroxaban—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000178	0.00778	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.000172	0.00749	CbGpPWpGaD
Rivaroxaban—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000166	0.00725	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—ITGAL—psoriasis	0.000163	0.0071	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—REN—psoriasis	0.000145	0.00634	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—NDUFA5—psoriasis	0.000144	0.00629	CbGpPWpGaD
Rivaroxaban—Oedema—Hydrocortisone—psoriasis	0.000142	0.000724	CcSEcCtD
Rivaroxaban—Tachycardia—Prednisolone—psoriasis	0.000141	0.000724	CcSEcCtD
Rivaroxaban—Asthenia—Mycophenolic acid—psoriasis	0.000141	0.000723	CcSEcCtD
Rivaroxaban—Infection—Hydrocortisone—psoriasis	0.000141	0.00072	CcSEcCtD
Rivaroxaban—Dyspepsia—Cyclosporine—psoriasis	0.00014	0.000718	CcSEcCtD
Rivaroxaban—Nausea—Hydroxyurea—psoriasis	0.00014	0.000715	CcSEcCtD
Rivaroxaban—Pruritus—Mycophenolic acid—psoriasis	0.000139	0.000713	CcSEcCtD
Rivaroxaban—Shock—Hydrocortisone—psoriasis	0.000139	0.000713	CcSEcCtD
Rivaroxaban—Nervous system disorder—Hydrocortisone—psoriasis	0.000139	0.00071	CcSEcCtD
Rivaroxaban—Eye disorder—Prednisone—psoriasis	0.000139	0.000709	CcSEcCtD
Rivaroxaban—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000139	0.000709	CcSEcCtD
Rivaroxaban—Tachycardia—Hydrocortisone—psoriasis	0.000138	0.000707	CcSEcCtD
Rivaroxaban—Infestation—Methotrexate—psoriasis	0.000138	0.000706	CcSEcCtD
Rivaroxaban—Infestation NOS—Methotrexate—psoriasis	0.000138	0.000706	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000137	0.000704	CcSEcCtD
Rivaroxaban—Skin disorder—Hydrocortisone—psoriasis	0.000137	0.000704	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Dexamethasone—psoriasis	0.000137	0.000704	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Betamethasone—psoriasis	0.000137	0.000704	CcSEcCtD
Rivaroxaban—Discomfort—Triamcinolone—psoriasis	0.000137	0.000703	CcSEcCtD
Rivaroxaban—Fatigue—Cyclosporine—psoriasis	0.000137	0.000703	CcSEcCtD
Rivaroxaban—Stevens-Johnson syndrome—Methotrexate—psoriasis	0.000137	0.0007	CcSEcCtD
Rivaroxaban—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000137	0.0007	CcSEcCtD
Rivaroxaban—Constipation—Cyclosporine—psoriasis	0.000136	0.000697	CcSEcCtD
Rivaroxaban—Pain—Cyclosporine—psoriasis	0.000136	0.000697	CcSEcCtD
Rivaroxaban—Dry mouth—Triamcinolone—psoriasis	0.000136	0.000696	CcSEcCtD
Rivaroxaban—Renal failure—Methotrexate—psoriasis	0.000136	0.000694	CcSEcCtD
Rivaroxaban—Angioedema—Betamethasone—psoriasis	0.000135	0.000693	CcSEcCtD
Rivaroxaban—Angioedema—Dexamethasone—psoriasis	0.000135	0.000693	CcSEcCtD
Rivaroxaban—Diarrhoea—Mycophenolic acid—psoriasis	0.000135	0.000689	CcSEcCtD
Rivaroxaban—Angiopathy—Prednisone—psoriasis	0.000134	0.000688	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000134	0.00586	CbGpPWpGaD
Rivaroxaban—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000134	0.000687	CcSEcCtD
Rivaroxaban—Immune system disorder—Prednisone—psoriasis	0.000134	0.000685	CcSEcCtD
Rivaroxaban—Malaise—Betamethasone—psoriasis	0.000134	0.000684	CcSEcCtD
Rivaroxaban—Malaise—Dexamethasone—psoriasis	0.000134	0.000684	CcSEcCtD
Rivaroxaban—Oedema—Triamcinolone—psoriasis	0.000133	0.000682	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Triamcinolone—psoriasis	0.000133	0.000682	CcSEcCtD
Rivaroxaban—Syncope—Dexamethasone—psoriasis	0.000133	0.00068	CcSEcCtD
Rivaroxaban—Syncope—Betamethasone—psoriasis	0.000133	0.00068	CcSEcCtD
Rivaroxaban—Constipation—Mycophenolate mofetil—psoriasis	0.000133	0.00068	CcSEcCtD
Rivaroxaban—Pain—Mycophenolate mofetil—psoriasis	0.000133	0.00068	CcSEcCtD
Rivaroxaban—ABCB1—Allograft Rejection—HLA-C—psoriasis	0.000132	0.00578	CbGpPWpGaD
Rivaroxaban—Infection—Triamcinolone—psoriasis	0.000132	0.000678	CcSEcCtD
Rivaroxaban—Hypotension—Hydrocortisone—psoriasis	0.000132	0.000677	CcSEcCtD
Rivaroxaban—ABCB1—Allograft Rejection—IL13—psoriasis	0.000132	0.00574	CbGpPWpGaD
Rivaroxaban—Haematuria—Methotrexate—psoriasis	0.000132	0.000673	CcSEcCtD
Rivaroxaban—Feeling abnormal—Cyclosporine—psoriasis	0.000131	0.000672	CcSEcCtD
Rivaroxaban—Shock—Triamcinolone—psoriasis	0.000131	0.000671	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Methotrexate—psoriasis	0.000131	0.000668	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Cyclosporine—psoriasis	0.00013	0.000667	CcSEcCtD
Rivaroxaban—Loss of consciousness—Betamethasone—psoriasis	0.00013	0.000667	CcSEcCtD
Rivaroxaban—Loss of consciousness—Dexamethasone—psoriasis	0.00013	0.000667	CcSEcCtD
Rivaroxaban—Dizziness—Mycophenolic acid—psoriasis	0.00013	0.000666	CcSEcCtD
Rivaroxaban—Epistaxis—Methotrexate—psoriasis	0.00013	0.000666	CcSEcCtD
Rivaroxaban—Tachycardia—Triamcinolone—psoriasis	0.00013	0.000666	CcSEcCtD
Rivaroxaban—Agranulocytosis—Methotrexate—psoriasis	0.000129	0.000659	CcSEcCtD
Rivaroxaban—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000128	0.000655	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000127	0.00065	CcSEcCtD
Rivaroxaban—Urticaria—Cyclosporine—psoriasis	0.000127	0.000648	CcSEcCtD
Rivaroxaban—Abdominal pain—Cyclosporine—psoriasis	0.000126	0.000644	CcSEcCtD
Rivaroxaban—Vomiting—Mycophenolic acid—psoriasis	0.000125	0.000641	CcSEcCtD
Rivaroxaban—Discomfort—Dexamethasone—psoriasis	0.000125	0.000638	CcSEcCtD
Rivaroxaban—Discomfort—Betamethasone—psoriasis	0.000125	0.000638	CcSEcCtD
Rivaroxaban—Dyspepsia—Hydrocortisone—psoriasis	0.000125	0.000638	CcSEcCtD
Rivaroxaban—Haemoglobin—Methotrexate—psoriasis	0.000125	0.000637	CcSEcCtD
Rivaroxaban—Rash—Mycophenolic acid—psoriasis	0.000124	0.000635	CcSEcCtD
Rivaroxaban—Dermatitis—Mycophenolic acid—psoriasis	0.000124	0.000635	CcSEcCtD
Rivaroxaban—Pain—Prednisolone—psoriasis	0.000124	0.000634	CcSEcCtD
Rivaroxaban—Haemorrhage—Methotrexate—psoriasis	0.000124	0.000634	CcSEcCtD
Rivaroxaban—Hepatitis—Methotrexate—psoriasis	0.000124	0.000634	CcSEcCtD
Rivaroxaban—Urticaria—Mycophenolate mofetil—psoriasis	0.000123	0.000632	CcSEcCtD
Rivaroxaban—Headache—Mycophenolic acid—psoriasis	0.000123	0.000631	CcSEcCtD
Rivaroxaban—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000123	0.000629	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—CYP2S1—psoriasis	0.000123	0.00534	CbGpPWpGaD
Rivaroxaban—Urinary tract disorder—Methotrexate—psoriasis	0.000122	0.000626	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000122	0.000625	CcSEcCtD
Rivaroxaban—Fatigue—Hydrocortisone—psoriasis	0.000122	0.000625	CcSEcCtD
Rivaroxaban—Urethral disorder—Methotrexate—psoriasis	0.000121	0.000622	CcSEcCtD
Rivaroxaban—ABCB1—Allograft Rejection—IL17A—psoriasis	0.000121	0.00529	CbGpPWpGaD
Rivaroxaban—Pain—Hydrocortisone—psoriasis	0.000121	0.00062	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Dexamethasone—psoriasis	0.000121	0.000619	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Betamethasone—psoriasis	0.000121	0.000619	CcSEcCtD
Rivaroxaban—Oedema—Betamethasone—psoriasis	0.000121	0.000619	CcSEcCtD
Rivaroxaban—Oedema—Dexamethasone—psoriasis	0.000121	0.000619	CcSEcCtD
Rivaroxaban—Infection—Dexamethasone—psoriasis	0.00012	0.000615	CcSEcCtD
Rivaroxaban—Infection—Betamethasone—psoriasis	0.00012	0.000615	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Prednisone—psoriasis	0.00012	0.000613	CcSEcCtD
Rivaroxaban—Feeling abnormal—Prednisolone—psoriasis	0.000119	0.000611	CcSEcCtD
Rivaroxaban—Anaemia—Prednisone—psoriasis	0.000119	0.00061	CcSEcCtD
Rivaroxaban—Shock—Betamethasone—psoriasis	0.000119	0.000609	CcSEcCtD
Rivaroxaban—Shock—Dexamethasone—psoriasis	0.000119	0.000609	CcSEcCtD
Rivaroxaban—Dyspnoea—Triamcinolone—psoriasis	0.000119	0.000608	CcSEcCtD
Rivaroxaban—Nervous system disorder—Betamethasone—psoriasis	0.000119	0.000607	CcSEcCtD
Rivaroxaban—Nervous system disorder—Dexamethasone—psoriasis	0.000119	0.000607	CcSEcCtD
Rivaroxaban—Tachycardia—Dexamethasone—psoriasis	0.000118	0.000604	CcSEcCtD
Rivaroxaban—Tachycardia—Betamethasone—psoriasis	0.000118	0.000604	CcSEcCtD
Rivaroxaban—Angioedema—Prednisone—psoriasis	0.000118	0.000604	CcSEcCtD
Rivaroxaban—Hypersensitivity—Cyclosporine—psoriasis	0.000117	0.000601	CcSEcCtD
Rivaroxaban—Dyspepsia—Triamcinolone—psoriasis	0.000117	0.0006	CcSEcCtD
Rivaroxaban—Erythema multiforme—Methotrexate—psoriasis	0.000117	0.0006	CcSEcCtD
Rivaroxaban—Nausea—Mycophenolic acid—psoriasis	0.000117	0.000599	CcSEcCtD
Rivaroxaban—Feeling abnormal—Hydrocortisone—psoriasis	0.000117	0.000597	CcSEcCtD
Rivaroxaban—Malaise—Prednisone—psoriasis	0.000116	0.000596	CcSEcCtD
Rivaroxaban—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000116	0.00505	CbGpPWpGaD
Rivaroxaban—Eye disorder—Methotrexate—psoriasis	0.000116	0.000593	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000116	0.000592	CcSEcCtD
Rivaroxaban—Syncope—Prednisone—psoriasis	0.000116	0.000592	CcSEcCtD
Rivaroxaban—Urticaria—Prednisolone—psoriasis	0.000115	0.000589	CcSEcCtD
Rivaroxaban—Cardiac disorder—Methotrexate—psoriasis	0.000115	0.000588	CcSEcCtD
Rivaroxaban—Fatigue—Triamcinolone—psoriasis	0.000115	0.000588	CcSEcCtD
Rivaroxaban—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000114	0.000586	CcSEcCtD
Rivaroxaban—Asthenia—Cyclosporine—psoriasis	0.000114	0.000585	CcSEcCtD
Rivaroxaban—Pain—Triamcinolone—psoriasis	0.000114	0.000583	CcSEcCtD
Rivaroxaban—Loss of consciousness—Prednisone—psoriasis	0.000113	0.000581	CcSEcCtD
Rivaroxaban—Hypotension—Betamethasone—psoriasis	0.000113	0.000578	CcSEcCtD
Rivaroxaban—Hypotension—Dexamethasone—psoriasis	0.000113	0.000578	CcSEcCtD
Rivaroxaban—Pruritus—Cyclosporine—psoriasis	0.000113	0.000577	CcSEcCtD
Rivaroxaban—ABCB1—Allograft Rejection—IL12B—psoriasis	0.000113	0.00491	CbGpPWpGaD
Rivaroxaban—Urticaria—Hydrocortisone—psoriasis	0.000112	0.000576	CcSEcCtD
Rivaroxaban—Angiopathy—Methotrexate—psoriasis	0.000112	0.000575	CcSEcCtD
Rivaroxaban—Immune system disorder—Methotrexate—psoriasis	0.000112	0.000573	CcSEcCtD
Rivaroxaban—Abdominal pain—Hydrocortisone—psoriasis	0.000112	0.000573	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Methotrexate—psoriasis	0.000112	0.000571	CcSEcCtD
Rivaroxaban—Asthenia—Mycophenolate mofetil—psoriasis	0.000111	0.000571	CcSEcCtD
Rivaroxaban—ABCB1—Allograft Rejection—HLA-E—psoriasis	0.00011	0.0048	CbGpPWpGaD
Rivaroxaban—Pruritus—Mycophenolate mofetil—psoriasis	0.00011	0.000563	CcSEcCtD
Rivaroxaban—Feeling abnormal—Triamcinolone—psoriasis	0.00011	0.000562	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000109	0.000558	CcSEcCtD
Rivaroxaban—Diarrhoea—Cyclosporine—psoriasis	0.000109	0.000558	CcSEcCtD
Rivaroxaban—Discomfort—Prednisone—psoriasis	0.000109	0.000556	CcSEcCtD
Rivaroxaban—Hypersensitivity—Prednisolone—psoriasis	0.000107	0.000547	CcSEcCtD
Rivaroxaban—Dyspepsia—Betamethasone—psoriasis	0.000106	0.000545	CcSEcCtD
Rivaroxaban—Dyspepsia—Dexamethasone—psoriasis	0.000106	0.000545	CcSEcCtD
Rivaroxaban—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000106	0.000544	CcSEcCtD
Rivaroxaban—Urticaria—Triamcinolone—psoriasis	0.000106	0.000542	CcSEcCtD
Rivaroxaban—Dizziness—Cyclosporine—psoriasis	0.000105	0.000539	CcSEcCtD
Rivaroxaban—Oedema—Prednisone—psoriasis	0.000105	0.000539	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Prednisone—psoriasis	0.000105	0.000539	CcSEcCtD
Rivaroxaban—Infection—Prednisone—psoriasis	0.000105	0.000536	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000104	0.000534	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Betamethasone—psoriasis	0.000104	0.000534	CcSEcCtD
Rivaroxaban—Back pain—Methotrexate—psoriasis	0.000104	0.000534	CcSEcCtD
Rivaroxaban—Hypersensitivity—Hydrocortisone—psoriasis	0.000104	0.000534	CcSEcCtD
Rivaroxaban—Fatigue—Betamethasone—psoriasis	0.000104	0.000534	CcSEcCtD
Rivaroxaban—Fatigue—Dexamethasone—psoriasis	0.000104	0.000534	CcSEcCtD
Rivaroxaban—Shock—Prednisone—psoriasis	0.000104	0.00053	CcSEcCtD
Rivaroxaban—Pain—Dexamethasone—psoriasis	0.000103	0.000529	CcSEcCtD
Rivaroxaban—Pain—Betamethasone—psoriasis	0.000103	0.000529	CcSEcCtD
Rivaroxaban—Nervous system disorder—Prednisone—psoriasis	0.000103	0.000529	CcSEcCtD
Rivaroxaban—Tachycardia—Prednisone—psoriasis	0.000103	0.000526	CcSEcCtD
Rivaroxaban—Dizziness—Mycophenolate mofetil—psoriasis	0.000103	0.000526	CcSEcCtD
Rivaroxaban—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000102	0.00447	CbGpPWpGaD
Rivaroxaban—Skin disorder—Prednisone—psoriasis	0.000102	0.000524	CcSEcCtD
Rivaroxaban—Asthenia—Hydrocortisone—psoriasis	0.000102	0.00052	CcSEcCtD
Rivaroxaban—Vomiting—Cyclosporine—psoriasis	0.000101	0.000518	CcSEcCtD
Rivaroxaban—Rash—Cyclosporine—psoriasis	0.0001	0.000514	CcSEcCtD
Rivaroxaban—Dermatitis—Cyclosporine—psoriasis	0.0001	0.000514	CcSEcCtD
Rivaroxaban—Pruritus—Hydrocortisone—psoriasis	0.0001	0.000513	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Methotrexate—psoriasis	0.0001	0.000512	CcSEcCtD
Rivaroxaban—Headache—Cyclosporine—psoriasis	9.98e-05	0.000511	CcSEcCtD
Rivaroxaban—Anaemia—Methotrexate—psoriasis	9.97e-05	0.00051	CcSEcCtD
Rivaroxaban—Feeling abnormal—Dexamethasone—psoriasis	9.97e-05	0.00051	CcSEcCtD
Rivaroxaban—Feeling abnormal—Betamethasone—psoriasis	9.97e-05	0.00051	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Dexamethasone—psoriasis	9.89e-05	0.000506	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Betamethasone—psoriasis	9.89e-05	0.000506	CcSEcCtD
Rivaroxaban—Vomiting—Mycophenolate mofetil—psoriasis	9.88e-05	0.000506	CcSEcCtD
Rivaroxaban—Hypersensitivity—Triamcinolone—psoriasis	9.82e-05	0.000503	CcSEcCtD
Rivaroxaban—Rash—Mycophenolate mofetil—psoriasis	9.8e-05	0.000501	CcSEcCtD
Rivaroxaban—Dermatitis—Mycophenolate mofetil—psoriasis	9.79e-05	0.000501	CcSEcCtD
Rivaroxaban—Headache—Mycophenolate mofetil—psoriasis	9.73e-05	0.000498	CcSEcCtD
Rivaroxaban—Malaise—Methotrexate—psoriasis	9.72e-05	0.000498	CcSEcCtD
Rivaroxaban—Diarrhoea—Hydrocortisone—psoriasis	9.68e-05	0.000496	CcSEcCtD
Rivaroxaban—Urticaria—Dexamethasone—psoriasis	9.61e-05	0.000492	CcSEcCtD
Rivaroxaban—Urticaria—Betamethasone—psoriasis	9.61e-05	0.000492	CcSEcCtD
Rivaroxaban—CYP3A4—Biological oxidations—CYP2S1—psoriasis	9.6e-05	0.00419	CbGpPWpGaD
Rivaroxaban—Dizziness—Prednisolone—psoriasis	9.58e-05	0.000491	CcSEcCtD
Rivaroxaban—Asthenia—Triamcinolone—psoriasis	9.56e-05	0.000489	CcSEcCtD
Rivaroxaban—Abdominal pain—Dexamethasone—psoriasis	9.56e-05	0.000489	CcSEcCtD
Rivaroxaban—Abdominal pain—Betamethasone—psoriasis	9.56e-05	0.000489	CcSEcCtD
Rivaroxaban—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	9.47e-05	0.00413	CbGpPWpGaD
Rivaroxaban—Nausea—Cyclosporine—psoriasis	9.46e-05	0.000484	CcSEcCtD
Rivaroxaban—Pruritus—Triamcinolone—psoriasis	9.43e-05	0.000483	CcSEcCtD
Rivaroxaban—Dizziness—Hydrocortisone—psoriasis	9.36e-05	0.000479	CcSEcCtD
Rivaroxaban—Dyspepsia—Prednisone—psoriasis	9.27e-05	0.000475	CcSEcCtD
Rivaroxaban—Nausea—Mycophenolate mofetil—psoriasis	9.23e-05	0.000472	CcSEcCtD
Rivaroxaban—Chest pain—Methotrexate—psoriasis	9.18e-05	0.00047	CcSEcCtD
Rivaroxaban—Rash—Prednisolone—psoriasis	9.14e-05	0.000468	CcSEcCtD
Rivaroxaban—Dermatitis—Prednisolone—psoriasis	9.13e-05	0.000467	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	9.12e-05	0.000467	CcSEcCtD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	9.1e-05	0.00397	CbGpPWpGaD
Rivaroxaban—Fatigue—Prednisone—psoriasis	9.08e-05	0.000465	CcSEcCtD
Rivaroxaban—Headache—Prednisolone—psoriasis	9.08e-05	0.000465	CcSEcCtD
Rivaroxaban—F10—Metabolism of proteins—ACE—psoriasis	9.07e-05	0.00396	CbGpPWpGaD
Rivaroxaban—Discomfort—Methotrexate—psoriasis	9.07e-05	0.000464	CcSEcCtD
Rivaroxaban—Constipation—Prednisone—psoriasis	9.01e-05	0.000461	CcSEcCtD
Rivaroxaban—Vomiting—Hydrocortisone—psoriasis	9e-05	0.000461	CcSEcCtD
Rivaroxaban—Rash—Hydrocortisone—psoriasis	8.92e-05	0.000457	CcSEcCtD
Rivaroxaban—Dermatitis—Hydrocortisone—psoriasis	8.92e-05	0.000456	CcSEcCtD
Rivaroxaban—Headache—Hydrocortisone—psoriasis	8.87e-05	0.000454	CcSEcCtD
Rivaroxaban—Dizziness—Triamcinolone—psoriasis	8.81e-05	0.000451	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Methotrexate—psoriasis	8.8e-05	0.000451	CcSEcCtD
Rivaroxaban—Infection—Methotrexate—psoriasis	8.74e-05	0.000448	CcSEcCtD
Rivaroxaban—Feeling abnormal—Prednisone—psoriasis	8.68e-05	0.000444	CcSEcCtD
Rivaroxaban—Asthenia—Betamethasone—psoriasis	8.68e-05	0.000444	CcSEcCtD
Rivaroxaban—Asthenia—Dexamethasone—psoriasis	8.68e-05	0.000444	CcSEcCtD
Rivaroxaban—Nervous system disorder—Methotrexate—psoriasis	8.63e-05	0.000442	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Prednisone—psoriasis	8.61e-05	0.000441	CcSEcCtD
Rivaroxaban—Nausea—Prednisolone—psoriasis	8.61e-05	0.000441	CcSEcCtD
Rivaroxaban—Pruritus—Betamethasone—psoriasis	8.56e-05	0.000438	CcSEcCtD
Rivaroxaban—Pruritus—Dexamethasone—psoriasis	8.56e-05	0.000438	CcSEcCtD
Rivaroxaban—Skin disorder—Methotrexate—psoriasis	8.55e-05	0.000438	CcSEcCtD
Rivaroxaban—Vomiting—Triamcinolone—psoriasis	8.47e-05	0.000434	CcSEcCtD
Rivaroxaban—Nausea—Hydrocortisone—psoriasis	8.41e-05	0.00043	CcSEcCtD
Rivaroxaban—Rash—Triamcinolone—psoriasis	8.4e-05	0.00043	CcSEcCtD
Rivaroxaban—Dermatitis—Triamcinolone—psoriasis	8.4e-05	0.00043	CcSEcCtD
Rivaroxaban—Urticaria—Prednisone—psoriasis	8.37e-05	0.000428	CcSEcCtD
Rivaroxaban—Headache—Triamcinolone—psoriasis	8.35e-05	0.000427	CcSEcCtD
Rivaroxaban—Abdominal pain—Prednisone—psoriasis	8.33e-05	0.000426	CcSEcCtD
Rivaroxaban—CYP3A4—Tryptophan metabolism—CAT—psoriasis	8.28e-05	0.00361	CbGpPWpGaD
Rivaroxaban—Diarrhoea—Dexamethasone—psoriasis	8.27e-05	0.000424	CcSEcCtD
Rivaroxaban—Diarrhoea—Betamethasone—psoriasis	8.27e-05	0.000424	CcSEcCtD
Rivaroxaban—ABCB1—Allograft Rejection—IL10—psoriasis	8.24e-05	0.00359	CbGpPWpGaD
Rivaroxaban—Hypotension—Methotrexate—psoriasis	8.22e-05	0.000421	CcSEcCtD
Rivaroxaban—ABCB1—Allograft Rejection—IL4—psoriasis	8.01e-05	0.00349	CbGpPWpGaD
Rivaroxaban—Dizziness—Betamethasone—psoriasis	8e-05	0.000409	CcSEcCtD
Rivaroxaban—Dizziness—Dexamethasone—psoriasis	8e-05	0.000409	CcSEcCtD
Rivaroxaban—Nausea—Triamcinolone—psoriasis	7.92e-05	0.000405	CcSEcCtD
Rivaroxaban—Dyspnoea—Methotrexate—psoriasis	7.85e-05	0.000402	CcSEcCtD
Rivaroxaban—ABCB1—Allograft Rejection—HLA-B—psoriasis	7.83e-05	0.00342	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	7.83e-05	0.00341	CbGpPWpGaD
Rivaroxaban—Hypersensitivity—Prednisone—psoriasis	7.76e-05	0.000397	CcSEcCtD
Rivaroxaban—Dyspepsia—Methotrexate—psoriasis	7.75e-05	0.000397	CcSEcCtD
Rivaroxaban—Vomiting—Betamethasone—psoriasis	7.69e-05	0.000394	CcSEcCtD
Rivaroxaban—Vomiting—Dexamethasone—psoriasis	7.69e-05	0.000394	CcSEcCtD
Rivaroxaban—Rash—Betamethasone—psoriasis	7.62e-05	0.00039	CcSEcCtD
Rivaroxaban—Rash—Dexamethasone—psoriasis	7.62e-05	0.00039	CcSEcCtD
Rivaroxaban—Dermatitis—Betamethasone—psoriasis	7.62e-05	0.00039	CcSEcCtD
Rivaroxaban—Dermatitis—Dexamethasone—psoriasis	7.62e-05	0.00039	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Methotrexate—psoriasis	7.6e-05	0.000389	CcSEcCtD
Rivaroxaban—Fatigue—Methotrexate—psoriasis	7.59e-05	0.000388	CcSEcCtD
Rivaroxaban—Headache—Dexamethasone—psoriasis	7.58e-05	0.000388	CcSEcCtD
Rivaroxaban—Headache—Betamethasone—psoriasis	7.58e-05	0.000388	CcSEcCtD
Rivaroxaban—Asthenia—Prednisone—psoriasis	7.56e-05	0.000387	CcSEcCtD
Rivaroxaban—Pain—Methotrexate—psoriasis	7.53e-05	0.000385	CcSEcCtD
Rivaroxaban—Pruritus—Prednisone—psoriasis	7.45e-05	0.000381	CcSEcCtD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	7.29e-05	0.00318	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—HLA-A—psoriasis	7.26e-05	0.00317	CbGpPWpGaD
Rivaroxaban—Feeling abnormal—Methotrexate—psoriasis	7.25e-05	0.000371	CcSEcCtD
Rivaroxaban—Diarrhoea—Prednisone—psoriasis	7.21e-05	0.000369	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Methotrexate—psoriasis	7.2e-05	0.000368	CcSEcCtD
Rivaroxaban—Nausea—Dexamethasone—psoriasis	7.18e-05	0.000368	CcSEcCtD
Rivaroxaban—Nausea—Betamethasone—psoriasis	7.18e-05	0.000368	CcSEcCtD
Rivaroxaban—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.14e-05	0.00311	CbGpPWpGaD
Rivaroxaban—Urticaria—Methotrexate—psoriasis	6.99e-05	0.000358	CcSEcCtD
Rivaroxaban—Dizziness—Prednisone—psoriasis	6.96e-05	0.000356	CcSEcCtD
Rivaroxaban—Abdominal pain—Methotrexate—psoriasis	6.96e-05	0.000356	CcSEcCtD
Rivaroxaban—Vomiting—Prednisone—psoriasis	6.7e-05	0.000343	CcSEcCtD
Rivaroxaban—F10—Hemostasis—NOS2—psoriasis	6.68e-05	0.00291	CbGpPWpGaD
Rivaroxaban—Rash—Prednisone—psoriasis	6.64e-05	0.00034	CcSEcCtD
Rivaroxaban—Dermatitis—Prednisone—psoriasis	6.63e-05	0.00034	CcSEcCtD
Rivaroxaban—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	6.63e-05	0.00289	CbGpPWpGaD
Rivaroxaban—Headache—Prednisone—psoriasis	6.6e-05	0.000338	CcSEcCtD
Rivaroxaban—Hypersensitivity—Methotrexate—psoriasis	6.48e-05	0.000332	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.42e-05	0.0028	CbGpPWpGaD
Rivaroxaban—Asthenia—Methotrexate—psoriasis	6.31e-05	0.000323	CcSEcCtD
Rivaroxaban—Nausea—Prednisone—psoriasis	6.26e-05	0.00032	CcSEcCtD
Rivaroxaban—Pruritus—Methotrexate—psoriasis	6.23e-05	0.000319	CcSEcCtD
Rivaroxaban—Diarrhoea—Methotrexate—psoriasis	6.02e-05	0.000308	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—CARM1—psoriasis	5.98e-05	0.00261	CbGpPWpGaD
Rivaroxaban—Dizziness—Methotrexate—psoriasis	5.82e-05	0.000298	CcSEcCtD
Rivaroxaban—F10—Metabolism of proteins—LEP—psoriasis	5.64e-05	0.00246	CbGpPWpGaD
Rivaroxaban—Vomiting—Methotrexate—psoriasis	5.6e-05	0.000286	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.59e-05	0.00244	CbGpPWpGaD
Rivaroxaban—Rash—Methotrexate—psoriasis	5.55e-05	0.000284	CcSEcCtD
Rivaroxaban—Dermatitis—Methotrexate—psoriasis	5.54e-05	0.000284	CcSEcCtD
Rivaroxaban—Headache—Methotrexate—psoriasis	5.51e-05	0.000282	CcSEcCtD
Rivaroxaban—Nausea—Methotrexate—psoriasis	5.23e-05	0.000268	CcSEcCtD
Rivaroxaban—ABCB1—Allograft Rejection—IFNG—psoriasis	4.84e-05	0.00211	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	4.83e-05	0.00211	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—CXCL8—psoriasis	4.5e-05	0.00196	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	4.22e-05	0.00184	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—NDUFA5—psoriasis	4.15e-05	0.00181	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—VEGFA—psoriasis	3.87e-05	0.00169	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—CXCL8—psoriasis	3.75e-05	0.00163	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	3.71e-05	0.00162	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—CAT—psoriasis	3.68e-05	0.00161	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—VEGFA—psoriasis	3.66e-05	0.0016	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CYP2S1—psoriasis	3.53e-05	0.00154	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—TNF—psoriasis	3.14e-05	0.00137	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—NDUFA5—psoriasis	3.13e-05	0.00137	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	3.12e-05	0.00136	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—TP53—psoriasis	2.92e-05	0.00127	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	2.91e-05	0.00127	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—APOE—psoriasis	2.86e-05	0.00125	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	2.78e-05	0.00121	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYP2S1—psoriasis	2.66e-05	0.00116	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PPARG—psoriasis	2.49e-05	0.00109	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.07e-05	0.000901	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.99e-05	0.000867	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—NDUFA5—psoriasis	1.93e-05	0.000842	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.81e-05	0.000787	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CARM1—psoriasis	1.72e-05	0.000752	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CYP2S1—psoriasis	1.64e-05	0.000716	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.55e-05	0.000675	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.36e-05	0.000595	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CARM1—psoriasis	1.3e-05	0.000568	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CAT—psoriasis	1.06e-05	0.000463	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—APOE—psoriasis	8.24e-06	0.000359	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CARM1—psoriasis	8.02e-06	0.00035	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CAT—psoriasis	8e-06	0.000349	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PPARG—psoriasis	7.18e-06	0.000313	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—APOE—psoriasis	6.22e-06	0.000271	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PPARG—psoriasis	5.42e-06	0.000236	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CAT—psoriasis	4.93e-06	0.000215	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—APOE—psoriasis	3.83e-06	0.000167	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PPARG—psoriasis	3.34e-06	0.000146	CbGpPWpGaD
